Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
M Rosellini, A Marchetti, V Mollica, A Rizzo… - Nature Reviews …, 2023 - nature.com
The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …
immunotherapy agents by regulatory agencies. However, objective and durable responses …
Updates on immunotherapy and immune landscape in renal clear cell carcinoma
Simple Summary Clear cell renal cell carcinomas (ccRCC) have several distinct
immunological features, including a high degree of immune infiltration and relatively low …
immunological features, including a high degree of immune infiltration and relatively low …
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open …
Background In the primary analysis of CheckMate 9ER, nivolumab plus cabozantinib
showed superior progression-free survival, overall survival, and objective response over …
showed superior progression-free survival, overall survival, and objective response over …
Management of metastatic clear cell renal cell carcinoma: ASCO guideline
WK Rathmell, RB Rumble… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To provide recommendations for the management of patients with metastatic
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …
The 2021 updated European association of urology guidelines on renal cell carcinoma: Immune checkpoint inhibitor–based combination therapies for treatment-naive …
The recent randomized controlled phase III CLEAR trial results are the last to complement
immune checkpoint inhibitor (ICI)-based doublet combination therapies for treatment-naïve …
immune checkpoint inhibitor (ICI)-based doublet combination therapies for treatment-naïve …
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an …
Summary Background In the CheckMate 9ER trial, patients with advanced renal cell
carcinoma who received first-line nivolumab plus cabozantinib had significantly better …
carcinoma who received first-line nivolumab plus cabozantinib had significantly better …
[HTML][HTML] Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials
F Massari, A Rizzo, V Mollica, M Rosellini… - European Journal of …, 2021 - Elsevier
Background Recent years have witnessed the advent of novel treatment options for
metastatic renal cell carcinoma (mRCC), including combination therapies with immune …
metastatic renal cell carcinoma (mRCC), including combination therapies with immune …
Treatment selection in first-line metastatic renal cell carcinoma—the contemporary treatment paradigm in the age of combination therapy: a review
Importance The treatment landscape of metastatic renal cell carcinoma has evolved rapidly
over the last decade. Recent combination approaches heralded by targeting immune …
over the last decade. Recent combination approaches heralded by targeting immune …
New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis
P Lombardi, M Filetti, R Falcone, R Di Bidino… - Cancer Treatment …, 2022 - Elsevier
Several first-line immune-checkpoints inhibitors (ICI) based combinations have been studied
in metastatic renal cell carcinoma (mRCC) without any direct comparison between the …
in metastatic renal cell carcinoma (mRCC) without any direct comparison between the …
Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review
AKA Lalani, DYC Heng, NS Basappa… - Therapeutic …, 2022 - journals.sagepub.com
Background: Renal cell carcinoma (RCC) is a common malignancy with approximately 30%
of cases diagnosed at the advanced or metastatic stage. While single-agent vascular …
of cases diagnosed at the advanced or metastatic stage. While single-agent vascular …